CYP2C19

Cytochrome P450 2C19 · P33261 · CYP2C19 on Sugi Atlas →

2,366,885 patent compounds predicted against CYP2C19, 1,448,636 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Fluconazole (SCHEMBL3151)	1.00	12/20
SCHEMBL5531	0.50	7/20
Ergotamine (SCHEMBL1483)	0.84	6/20
SCHEMBL2386	1.00	5/20
Miconazole (SCHEMBL2866)	1.00	5/20
(R)-Miconazole (SCHEMBL2867)	1.00	5/20
Nifedipine (SCHEMBL3968)	1.00	5/20
Miconazole (SCHEMBL3366)	0.98	5/20
(R)-Miconazole (SCHEMBL3367)	0.98	5/20
SCHEMBL6803	0.56	5/20
SCHEMBL6254	0.46	5/20
Ketotifen (SCHEMBL4436)	1.00	4/20
Noscapine (SCHEMBL4559)	1.00	4/20
SCHEMBL4546	0.73	4/20
Butylated Hydroxytoluene (SCHEMBL3950)	0.65	4/20
Aluminum Clofibrate (SCHEMBL3344)	0.62	4/20
Omeprazole (SCHEMBL1192)	0.60	4/20
Thiamiprine (SCHEMBL4851)	0.53	4/20
SCHEMBL5264	0.46	4/20
Doxylamine (SCHEMBL4709)	0.44	4/20

Clinical trials — most relevant to CYP2C19 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Adjunctive Cilostazol Versus High Maintenance-dose Clopidogrel According to Cytochrome 2C19 Polymorphism	PHASE4	COMPLETED
Clopidogrel Proton-Pump Inhibitors Study	PHASE4	WITHDRAWN
Effect of Proton Pump Inhibitor on Residual Platelet Reactivity After Clopidogrel in Homogenous Genetic Strata	PHASE4	UNKNOWN
Customized Choice of Oral P2Y12 Receptor Blocker	PHASE4	UNKNOWN
Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome	PHASE4	COMPLETED
Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome	PHASE4	COMPLETED
Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism	PHASE3	UNKNOWN
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients	PHASE2	COMPLETED
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia	PHASE2	COMPLETED
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL	PHASE1/PHASE2	UNKNOWN
A Study of TY-1091 in Patients With Advanced Solid Tumors	PHASE1/PHASE2	UNKNOWN
Asciminib in HER2+ Breast Cancer Brain Metastases	PHASE1/PHASE2	NOT_YET_RECRUITING
A Study to Evaluate the Effect of Genotype on LY2216684	PHASE1	COMPLETED
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients	PHASE1	COMPLETED
Study of E3810 for Healthy Japanese Male (Under Fasting Condition)	PHASE1	COMPLETED
A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)	PHASE1	COMPLETED
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot	PHASE1	COMPLETED
A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations	PHASE1	COMPLETED
Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel	PHASE1	COMPLETED
A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel	PHASE1	COMPLETED
Clopidogrel Preventive Effect Based on CYP2C19 Genotype in Ischemic Stroke	nan	COMPLETED
Pharmacogenomic Profiling of Pediatric Patients	nan	COMPLETED
CYP2C19 Variants and Limonene Metabolism	nan	RECRUITING
Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy	nan	COMPLETED
Precision PCI Registry	nan	ACTIVE_NOT_RECRUITING
Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort	nan	WITHDRAWN
Impact of Genotyping P450 2C19 on Hospitalization Period	nan	WITHDRAWN
Cohort Study of Clopidogrel and Proton Pump Inhibitors	nan	COMPLETED
Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events	nan	ACTIVE_NOT_RECRUITING
Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP2C19 binder may also engage these)

Protein	Name	Similarity
Q08078	—	1.000	Q08078 →
P33263	—	1.000	P33263 →
CYP2C8	Cytochrome P450 2C8	1.000	landscape →
Q64458	—	1.000	Q64458 →
P15123	—	1.000	P15123 →
P33262	—	1.000	P33262 →
P56654	—	0.998	P56654 →
P05179	—	0.997	P05179 →
CYP2C9	Cytochrome P450 2C9	0.997	landscape →
P33264	—	0.996	P33264 →
P56656	—	0.996	P56656 →
Q9D816	—	0.995	Q9D816 →
Q64583	—	0.995	Q64583 →
CYP2A7	Cytochrome P450 2A7 (EC 1.14.14.1) (CYPIIA7)	0.995	landscape →
P11372	—	0.995	P11372 →
P00180	—	0.993	P00180 →
P17666	—	0.992	P17666 →
O55071	—	0.992	O55071 →
CYP2A13	Cytochrome P450 2A13	0.992	landscape →
P33265	—	0.992	P33265 →
P00181	—	0.992	P00181 →
P00182	—	0.991	P00182 →
E9Q5K4	—	0.991	E9Q5K4 →
P00179	—	0.991	P00179 →
P24470	—	0.991	P24470 →
CYP2C18	Cytochrome P450 2C18	0.990	landscape →
P08683	—	0.990	P08683 →
Q91X77	—	0.989	Q91X77 →
P20812	—	0.989	P20812 →
P33273	—	0.988	P33273 →